Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
31,889
archived clinical trials in
Blood Cancer

Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
Status: Enrolling
Updated:  3/15/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
Protocol to Obtain Blood for Discovery of Novel Biomarkers and Potential Therapeutic Targets in Chronic Lymphocytic Leukemia
Status: Enrolling
Updated: 3/15/2018
Dartmouth Hitchcock Medical Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Study of Everolimus (RAD001) in Combination With Lenalidomide
Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma
Status: Enrolling
Updated:  3/15/2018
Grady Health System
mi
from
Atlanta, GA
Study of Everolimus (RAD001) in Combination With Lenalidomide
Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma
Status: Enrolling
Updated: 3/15/2018
Grady Health System
mi
from
Atlanta, GA
Click here to add this to my saved trials
Study of Everolimus (RAD001) in Combination With Lenalidomide
Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma
Status: Enrolling
Updated:  3/15/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Study of Everolimus (RAD001) in Combination With Lenalidomide
Phase I Study of Everolimus (RAD001) in Combination With Lenalidomide in Patients With Advanced Solid Malignancies Enriched for Renal Cell Carcinoma
Status: Enrolling
Updated: 3/15/2018
Emory University/Winship Cancer Institute
mi
from
Atlanta, GA
Click here to add this to my saved trials
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
A Pilot Clinical Trial of Mitomycin C Modulation of Multidrug Resistance Proteins and a Phase I Evaluation of Mitomycin C and Mitoxantrone in Patients With Acute Myelogenous Leukemia
Status: Enrolling
Updated:  3/15/2018
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Mitomycin and Mitoxantrone in Treating Patients With Acute Myelogenous Leukemia
A Pilot Clinical Trial of Mitomycin C Modulation of Multidrug Resistance Proteins and a Phase I Evaluation of Mitomycin C and Mitoxantrone in Patients With Acute Myelogenous Leukemia
Status: Enrolling
Updated: 3/15/2018
Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
Improving Blood Stem Cell Collection and Transplant Procedures
Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using Ex Vivo CD3, CD19 Depletion and CD34 Selection
Status: Enrolling
Updated:  3/16/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Improving Blood Stem Cell Collection and Transplant Procedures
Peripheral Blood Stem Cell Allotransplantation for Hematological Malignancies Using Ex Vivo CD3, CD19 Depletion and CD34 Selection
Status: Enrolling
Updated: 3/16/2018
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
LCCC 1111: An Open-Label Dose-Finding Study of Lenalidomide as Reinduction/ Consolidation Followed by Lenalidomide Maintenance Therapy for Adults ≥ 60 Years of Age With Acute Myeloid Leukemia (AML) in Partial or Complete Response Following Conventional Induction Therapy
Status: Enrolling
Updated:  3/20/2018
Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Lenalidomide as Consolidation and Maintenance in Adults >/= 60 Years of Age With AML Following Standard Induction
LCCC 1111: An Open-Label Dose-Finding Study of Lenalidomide as Reinduction/ Consolidation Followed by Lenalidomide Maintenance Therapy for Adults ≥ 60 Years of Age With Acute Myeloid Leukemia (AML) in Partial or Complete Response Following Conventional Induction Therapy
Status: Enrolling
Updated: 3/20/2018
Univ. of North Carolina at Chapel Hill, Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Yale-New Haven Hospital North Haven Medical Center
mi
from
North Haven, CT
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Yale-New Haven Hospital North Haven Medical Center
mi
from
North Haven, CT
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Johns Hopkins University-Sidney Kimmel Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Washington University School of Medicine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Columbia University Herbert Irving Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
UNC Lineberger Comprehensive Cancer Center
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Texas Oncology at Baylor Irving Cancer Center
mi
from
Irving, TX
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Texas Oncology at Baylor Irving Cancer Center
mi
from
Irving, TX
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Yale University
mi
from
New Haven, CT
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Yale University
mi
from
New Haven, CT
Click here to add this to my saved trials
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated:  3/20/2018
Baylor University Medical Center
mi
from
Dallas, TX
Ipilimumab in Treating Patients With Relapsed or Refractory High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia
A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia With Minimal Residual Disease
Status: Enrolling
Updated: 3/20/2018
Baylor University Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  3/20/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 3/20/2018
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated:  3/20/2018
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
A Phase I/II Study of MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
Status: Enrolling
Updated: 3/20/2018
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Mayo Clinic Arizona
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Medical Center of Aurora
mi
from
Aurora, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Medical Center of Aurora
mi
from
Aurora, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Boulder Community Hospital
mi
from
Boulder, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Boulder Community Hospital
mi
from
Boulder, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Penrose-Saint Francis Healthcare
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Porter Adventist Hospital
mi
from
Denver, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Porter Adventist Hospital
mi
from
Denver, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Presbyterian - Saint Lukes Medical Center - Health One
mi
from
Denver, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Presbyterian - Saint Lukes Medical Center - Health One
mi
from
Denver, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Rose Medical Center
mi
from
Denver, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Rose Medical Center
mi
from
Denver, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Swedish Medical Center
mi
from
Englewood, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Swedish Medical Center
mi
from
Englewood, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Saint Mary's Hospital and Regional Medical Center
mi
from
Grand Junction, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Saint Mary's Hospital and Regional Medical Center
mi
from
Grand Junction, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
North Colorado Medical Center
mi
from
Greeley, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
North Colorado Medical Center
mi
from
Greeley, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Saint Anthony Hospital
mi
from
Lakewood, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Saint Anthony Hospital
mi
from
Lakewood, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Sky Ridge Medical Center
mi
from
Lone Tree, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Longmont United Hospital
mi
from
Longmont, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Longmont United Hospital
mi
from
Longmont, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
McKee Medical Center
mi
from
Loveland, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
McKee Medical Center
mi
from
Loveland, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
St. Mary - Corwin Medical Center
mi
from
Pueblo, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
St. Mary - Corwin Medical Center
mi
from
Pueblo, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
North Suburban Medical Center
mi
from
Thornton, CO
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
North Suburban Medical Center
mi
from
Thornton, CO
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Saint Francis Hospital - Wilmington
mi
from
Wilmington, DE
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Saint Francis Hospital - Wilmington
mi
from
Wilmington, DE
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Broward Health Medical Center
mi
from
Fort Lauderdale, FL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Broward Health Medical Center
mi
from
Fort Lauderdale, FL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
University of Miami Miller School of Medicine-Sylvester Cancer Center
mi
from
Miami, FL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
University Cancer and Blood Center LLC
mi
from
Athens, GA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
University Cancer and Blood Center LLC
mi
from
Athens, GA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Memorial University Medical Center
mi
from
Savannah, GA
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Memorial University Medical Center
mi
from
Savannah, GA
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Saint Joseph Medical Center
mi
from
Bloomington, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Saint Joseph Medical Center
mi
from
Bloomington, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Graham Hospital Association
mi
from
Canton, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Graham Hospital Association
mi
from
Canton, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Memorial Hospital
mi
from
Carthage, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Memorial Hospital
mi
from
Carthage, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Hematology and Oncology Associates
mi
from
Chicago, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Hematology and Oncology Associates
mi
from
Chicago, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Northwestern University
mi
from
Chicago, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Jesse Brown Veterans Affairs Medical Center
mi
from
Chicago, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Jesse Brown Veterans Affairs Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Rush University Medical Center
mi
from
Chicago, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Rush University Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Mercy Hospital and Medical Center
mi
from
Chicago, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Mercy Hospital and Medical Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Swedish Covenant Hospital
mi
from
Chicago, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Swedish Covenant Hospital
mi
from
Chicago, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Decatur Memorial Hospital
mi
from
Decatur, IL
Click here to add this to my saved trials
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated:  3/20/2018
Eureka Hospital
mi
from
Eureka, IL
Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure or Patients Over Age 60 in First Remission
Status: Enrolling
Updated: 3/20/2018
Eureka Hospital
mi
from
Eureka, IL
Click here to add this to my saved trials